Picture of NANOSONICS logo

NAN — NANOSONICS News Story

0.000.00%
au flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Shares of Australia's Nanosonics over-valued - Morningstar

** Brokerage Morningstar believes shares of infection
prevention co Nanosonics  NAN.AX  are over-valued, says EBIT
margins of co are set to fall due to lower-margin capital
revenue, among others
    ** Morningstar maintains A$4.00 fair value estimate for
"narrow-moat" Nanosonics
    ** Brokerage's fiscal 2024 EBIT forecast of A$14 million
($9.46 million), a 21% decrease on fiscal 2023, remains broadly
unchanged
    ** "Conditions are challenging given hospital budget
pressures" - brokerage
    ** Three of 11 analysts rate the stock "buy" or higher, six
"hold" and two "sell" or lower; their median PT is A$4.93 – LSEG
    ** Stock up 6.1% YTD, as of last close

    
($1 = 1.4795 Australian dollars)

 (Reporting by Adwitiya Srivastava in Bengaluru)
 ((Adwitiya.Srivastava@thomsonreuters.com;))

Recent news on NANOSONICS

See all news